Madrigal Pharmaceuticals
MDGL
487.72
-8.73
-1.76%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
487.72
-8.73
-1.76%
Live - 5344 symbols - heartbeat 426s ago
· 2026-10-08 07:10
Pre-market
498.89
+2.29%
After-hours
487.72
0.00%
- Market cap
- 11.27B
- P/E (TTM)i
- -34.86
- P/Bi
- 21.52
- EPSi
- -12.85
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on MDGL?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 12 analysts
Buy
Avg price target
685.58 +40.6%
Price target rangecurrent 487.72
Low553.00
Avg685.58
High962.00
Buy 92%
Hold 8%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Barclays | -- | BUY | 962.00 |
| 2026-09-24 | Goldman Sachs | -- | BUY | 704.00 |
| 2026-09-23 | Citi | -- | BUY | 725.00 |
| 2026-08-11 | CCORF | -- | BUY | 612.00 |
| 2026-08-04 | Wolfe Research | -- | BUY | 605.00 |
| 2026-08-03 | Barclays | -- | BUY | 962.00 |
| 2026-07-31 | Truist Financial | -- | BUY | 709.00 |
| 2026-07-31 | H.C. Wainwright | -- | BUY | 620.00 |
| 2026-07-30 | TD Cowen | -- | BUY | 644.00 |
| 2026-07-29 | CCORF | -- | BUY | 587.00 |
| 2026-07-27 | Wells Fargo | -- | BUY | 685.00 |
| 2026-07-22 | BofA Securities | -- | HOLD | 553.00 |
| 2026-07-21 | UBS | -- | BUY | 669.00 |
| 2026-07-20 | TD Cowen | -- | BUY | 644.00 |
| 2026-07-17 | Citizens JMP | -- | BUY | 739.00 |
| 2026-07-14 | Truist Financial | -- | BUY | -- |
| 2026-07-13 | BofA Securities | -- | HOLD | 542.00 |
| 2026-07-13 | Barclays | -- | BUY | 964.00 |
| 2026-06-29 | Piper Sandler | -- | BUY | 900.00 |
| 2026-06-24 | Piper Sandler | -- | BUY | 900.00 |
| 2026-06-11 | BofA Securities | -- | HOLD | 542.00 |
| 2026-05-28 | H.C. Wainwright | -- | BUY | 620.00 |
| 2026-05-13 | Truist Financial | -- | BUY | 709.00 |
| 2026-05-08 | Barclays | -- | BUY | 964.00 |
| 2026-05-07 | CCORF | -- | BUY | 578.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Wolfe Research moved from Hold to Buy on 2026-08-04.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-04 | Wolfe Research | HOLD → BUY | 605.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±11.57% | -9.83% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±9.99% | +7.42% (in line) |
| 2025/Q4 | 2026-02-19 | -- | ±6.71% | -11.11% (beat) |
| 2025/Q3 | 2025-11-04 | -- | ±13.94% | +7.83% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±10.86% | +8.59% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±13.18% | -1.86% (in line) |
| 2024/Q4 | 2025-02-26 | -- | ±15.36% | +14.99% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±18.10% | +20.10% (beat) |
| 2024/Q2 | 2024-08-07 | -- | ±13.17% | -12.18% (in line) |
| 2024/Q1 | 2024-05-07 | -- | ±9.55% | -7.48% (in line) |
| 2022/Q1 | 2022-05-09 | -- | -- | -10.14% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:10:38 · For reference only, not investment advice and not tailored to your situation.